Recorded July 21, 2023. This transcript has been edited for clarity.
Ileana L. Piña, MD, MPH: Hello, everyone. I'm Ileana Piña, professor of medicine at Jefferson University Hospital in Philadelphia. I'm the chief of quality. This is my blog. We have been hearing a lot of conversation about obesity. It's coming out of our endocrine division and our weight management division. And the patients are asking for things like bariatric surgery and maybe a holistic program of weight loss.
A lot of the primary care doctors are starting to recommend glucagon-like peptide-1 (GLP-1) receptor agonists for those patients. But we deal with patients with heart failure with preserved ejection fraction (HFpEF), and a lot of our phenotypes are patients with obesity who happen to have hypertension and/or diabetes, and they are difficult to manage.
Inflammation, Obesity, and HFpEF
Piña: For today's conversation, there is nobody better than Dr Ambarish Pandey, who has a HFpEF program at the University of Texas Southwestern. Ambarish, welcome. Give me your thoughts overall about the link between obesity, inflammation, and HFpEF.
Ambarish Pandey, MD: Thank you, Dr Piña. I'm excited to be on your blog and I'm glad that we are discussing such an important topic.
Cardiologists, Patients Can Talk Drug Costs
Early or Delayed AF Ablation After Heart Failure Hospitalization?
Skill Checkup: A 69-Year-Old Woman With Worsening Heart Failure and Iron Deficiency
COMMENTARY
GLP-1 Agonists in HFpEF With Obesity: Are We There Yet?
Ileana L. Piña, MD, MPH; Ambarish Pandey, MD
DisclosuresJuly 27, 2023
Recorded July 21, 2023. This transcript has been edited for clarity.
Ileana L. Piña, MD, MPH: Hello, everyone. I'm Ileana Piña, professor of medicine at Jefferson University Hospital in Philadelphia. I'm the chief of quality. This is my blog. We have been hearing a lot of conversation about obesity. It's coming out of our endocrine division and our weight management division. And the patients are asking for things like bariatric surgery and maybe a holistic program of weight loss.
A lot of the primary care doctors are starting to recommend glucagon-like peptide-1 (GLP-1) receptor agonists for those patients. But we deal with patients with heart failure with preserved ejection fraction (HFpEF), and a lot of our phenotypes are patients with obesity who happen to have hypertension and/or diabetes, and they are difficult to manage.
Inflammation, Obesity, and HFpEF
Piña: For today's conversation, there is nobody better than Dr Ambarish Pandey, who has a HFpEF program at the University of Texas Southwestern. Ambarish, welcome. Give me your thoughts overall about the link between obesity, inflammation, and HFpEF.
Ambarish Pandey, MD: Thank you, Dr Piña. I'm excited to be on your blog and I'm glad that we are discussing such an important topic.
© 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ileana L. Piña, Ambarish Pandey. GLP-1 Agonists in HFpEF With Obesity: Are We There Yet? - Medscape - Jul 27, 2023.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Ileana L. Piña, MD, MPH
Professor of Medicine/Cardiology/Heart Failure/Transplant; Quality Officer, Cardiovascular Line, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania; Clinical Professor of Medicine, Central Michigan University College of Medicine, Mount Pleasant, Michigan; Adjunct Professor of Epidemiology and Biostatistics, Population & Quantitative Health Sciences, Case Western University, Cleveland, Ohio
Disclosure: Ileana L. Piña, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, office, partner, employee, advisor, consultant, or trustee for: US Food and Drug Administration; Center for Devices and Radiological Health
Ambarish Pandey, MD
Associate Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center; Medical Director, Heart Failure with Preserved Ejection Fraction Program, Department of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas
Disclosure: Ambarish Pandey, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Tricog Health Inc; Lily USA; Rivus; Cytokinetics; Emmi Solutions; Axon Therapies; Sarfez Pharmaceuticals; Alleviant Me
Received research grant from: Gilead; National Institutes of Health; Applied Therapeutics; HeartSciences